Aligos Therapeutics, Inc.

Aligos Therapeutics Inc. is a clinical-stage biotechnology company specializing in the discovery and development of targeted antiviral and liver disease therapies. The firm focuses on unmet medical needs in chronic liver and viral diseases, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and coronavirus infections. Its pipeline includes innovative oral small molecule drug candidates such as Pevifoscorvir sodium, a capsid assembly modulator targeting chronic hepatitis B virus infection, and ALG-055009, a thyroid hormone receptor beta agonist for metabolic dysfunction-associated steatohepatitis. Leveraging a science-driven approach and expertise in hepatology and virology, Aligos aims to develop best-in-class molecules with enhanced pharmacologic properties to improve patient outcomes. The company’s research collaborations and licensing agreements support its efforts to pioneer therapies addressing substantial global health burdens linked to liver disease and viral infections.